Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection

Wieslaw M. Kazmierski, Kristjan S. Gudmundsson, Stephen C. Piscitelli, Chapter 19 Small Molecule CCR5 and CXCR4-Based Viral Entry Inhibitors for Anti-HIV Therapy Currently in Development Annual Reports in Medicinal Chemistry Volume 42. ,vol. 42, pp. 301- 320 ,(2007) , 10.1016/S0065-7743(07)42019-X

Julie Strizki, Targeting HIV attachment and entry for therapy. Advances in pharmacology (San Diego). ,vol. 56, pp. 93- 120 ,(2008) , 10.1016/S1054-3589(07)56004-7

Robert A. Ogert, Lisa Wojcik, Catherine Buontempo, Lei Ba, Peter Buontempo, Robert Ralston, Julie Strizki, John A. Howe, Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120 Virology. ,vol. 373, pp. 387- 399 ,(2008) , 10.1016/J.VIROL.2007.12.009

J. Phillip Kennedy, Lyndsey Williams, Thomas M. Bridges, R. Nathan Daniels, David Weaver, Craig W. Lindsley, Application of combinatorial chemistry science on modern drug discovery. ACS Combinatorial Science. ,vol. 10, pp. 345- 354 ,(2008) , 10.1021/CC700187T

Kathleen A Cox, Kimberly Dunn-Meynell, Walter A Korfmacher, Lisa Broske, Amin A Nomeir, Chin-Chung Lin, Mitchell N Cayen, William H Barr, Novel in vivo procedure for rapid pharmacokinetic screening of discovery compounds in rats Drug Discovery Today. ,vol. 4, pp. 232- 237 ,(1999) , 10.1016/S1359-6446(98)01299-9

Roy M Gulick, Jacob Lalezari, James Goodrich, Nathan Clumeck, Edwin DeJesus, Andrzej Horban, Jeffrey Nadler, Bonaventura Clotet, Anders Karlsson, Michael Wohlfeiler, John B Montana, Mary McHale, John Sullivan, Caroline Ridgway, Steve Felstead, Michael W Dunne, Elna Van Der Ryst, Howard Mayer, None, Maraviroc for Previously Treated Patients with R5 HIV-1 Infection The New England Journal of Medicine. ,vol. 359, pp. 1429- 1441 ,(2008) , 10.1056/NEJMOA0803152

Jay L Duffner, Paul A Clemons, Angela N Koehler, A pipeline for ligand discovery using small-molecule microarrays. Current Opinion in Chemical Biology. ,vol. 11, pp. 74- 82 ,(2007) , 10.1016/J.CBPA.2006.11.031

Anandan Palani, Sherry Shapiro, John W. Clader, William J. Greenlee, Kathleen Cox, Julie Strizki, Michael Endres, Bahige M. Baroudy, Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. Journal of Medicinal Chemistry. ,vol. 44, pp. 3339- 3342 ,(2001) , 10.1021/JM015526O

Jayaram R. Tagat, Ruo W. Steensma, Stuart W. McCombie, Dennis V. Nazareno, Sue-Ing Lin, Bernard R. Neustadt, Kathleen Cox, Serena Xu, Lisa Wojcik, Michael G. Murray, Nicole Vantuno, Bahige M. Baroudy, Julie M. Strizki, Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. II. Discovery of 1-[(2,4-Dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoro- methyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-Oxide (Sch-350634), an Orally Bioavailable, Potent CCR5 Antagonist Journal of Medicinal Chemistry. ,vol. 44, pp. 3343- 3346 ,(2001) , 10.1021/JM0155401

P Yeni, A Lamarca, D Berger, P Cimoch, A Lazzarin, P Salvato, FM Smaill, E Teofilo, SJ Madison, WG Nichols, KK Adkison, T Bonny, J Millard, D McCarty, EPIC (CCR100136) Study Team, None, Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136). Hiv Medicine. ,vol. 10, pp. 116- 124 ,(2009) , 10.1111/J.1468-1293.2008.00660.X